Marie-christiane M. Vekemans

Antwerpen, VLG, Belgium

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 51 publications

Belgian recommendations for tissue diagnosis of amyloidosis.

Belgian recommendations for tissue diagnosis of amyloidosis.

Journal: Acta clinica Belgica

Published: April 27, 2026

Autologous stem cell transplantation versus consolidation chemotherapy as postremission treatment in newly diagnosed favorable- and intermediate-risk patients with AML: A comparative analysis of HOVON-SAKK-Nordic trials.

Autologous stem cell transplantation versus consolidation chemotherapy as postremission treatment in newly diagnosed favorable- and intermediate-risk patients with AML: A comparative analysis of HOVON-SAKK-Nordic trials.

Journal: HemaSphere

Published: April 21, 2026

Multidisciplinary approach to managing GPRC5D-related adverse events in relapsed or refractory multiple myeloma patients.

Multidisciplinary approach to managing GPRC5D-related adverse events in relapsed or refractory multiple myeloma patients.

Journal: Annals of hematology

Published: March 25, 2026

Zero echo time MRI with deep learning reconstruction and chemical shift correction for detecting osteolytic myeloma lesions.

Zero echo time MRI with deep learning reconstruction and chemical shift correction for detecting osteolytic myeloma lesions.

Journal: European radiology experimental

Published: November 14, 2025

Venetoclax combinations in untreated CLL: 5-year results and patient-reported outcome analysis of the CLL13/GAIA trial.

Venetoclax combinations in untreated CLL: 5-year results and patient-reported outcome analysis of the CLL13/GAIA trial.

Journal: Blood

Published: October 22, 2025

Venetoclax combinations in untreated CLL: 5-year results and patient-reported outcomes analysis of the CLL13/GAIA trial.

Venetoclax combinations in untreated CLL: 5-year results and patient-reported outcomes analysis of the CLL13/GAIA trial.

Journal: Blood

Published: October 22, 2025

Linvoseltamab in Patients With Relapsed/Refractory Multiple Myeloma in the LINKER-MM1 Study: Longer Follow-Up and Subgroup Analyses.

Linvoseltamab in Patients With Relapsed/Refractory Multiple Myeloma in the LINKER-MM1 Study: Longer Follow-Up and Subgroup Analyses.

Journal: Clinical lymphoma, myeloma & leukemia

Published: September 23, 2025

35 years of academic trials focusing on high-dose therapy and autologous stem cell transplantation: the Intergroupe Francophone du Myélome (IFM) experience.

35 years of academic trials focusing on high-dose therapy and autologous stem cell transplantation: the Intergroupe Francophone du Myélome (IFM) experience.

Journal: Blood cancer journal

Published: July 07, 2025

Frail subgroups determine heterogeneous outcomes in older patients with NDMM: long-term follow-up of the HOVON 143 trial.

Frail subgroups determine heterogeneous outcomes in older patients with NDMM: long-term follow-up of the HOVON 143 trial.

Journal: Blood advances

Published: June 09, 2025

A revised prognostic model for patients with acute myeloid leukemia and first relapse.

A revised prognostic model for patients with acute myeloid leukemia and first relapse.

Journal: Blood advances

Published: January 06, 2025

Prospective comparison between geriatric assessment and clinical evaluation in 200 newly diagnosed older adults with multiple myeloma.

Prospective comparison between geriatric assessment and clinical evaluation in 200 newly diagnosed older adults with multiple myeloma.

Journal: Journal of geriatric oncology

Published: November 25, 2024

MRI-based Zero Echo Time and Black Bone Pseudo-CT Compared with Whole-Body CT to Detect Osteolytic Lesions in Multiple Myeloma.

MRI-based Zero Echo Time and Black Bone Pseudo-CT Compared with Whole-Body CT to Detect Osteolytic Lesions in Multiple Myeloma.

Journal: Radiology

Published: October 08, 2024

Showing 1-12 of 51

Last Updated: 09/26/2026